Adelaide Research & Scholarship: Search

Search

Results 31-40 of 97 (Search time: 0.002 seconds).

previous
1
2
3
4
5
6
7
...
10
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2014	Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells	Nievergall, E.; Ramshaw, H.; Yong, A.; Biondo, M.; Busfield, S.; Vairo, G.; Lopez, A.; Hughes, T.; White, D.; Hiwase, D.
	2018	ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells	Eadie, L.; Dang, P.; Goyne, J.; Hughes, T.; White, D.; Maga, G.
	2013	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML	Branford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
	2012	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia	Yin, O.; Giles, F.; Baccarani, M.; le Coutre, P.; Chiparus, O.; Gallagher, N.; Saglio, G.; Hughes, T.; Hochhaus, A.; Kantarjian, H.; Larson, R.
	2013	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study	Ross, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
	2013	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase	Hochhaus, A.; Saglio, G.; Larson, R.; Kim, D.; Etienne, G.; Rosti, G.; De Souza, C.; Kurokawa, M.; Kalaycio, M.; Hoenekopp, A.; Fan, X.; Shou, Y.; Kantarjian, H.; Hughes, T.
	2013	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013	Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al.
	2013	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy	Angelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
	2015	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase	Hughes, T.; Saglio, G.; Quintás-Cardama, A.; Mauro, M.; Kim, D.; Lipton, J.; Bradley-Garelik, M.; Ukropec, J.; Hochhaus, A.
	2016	BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia	Latham, S.; Bartley, P.; Budgen, B.; Ross, D.; Hughes, E.; Branford, S.; White, D.; Hughes, T.; Morley, A.